Animal and human clinical trials often use significantly large dosages.
In response to the original poster. Not trying to be pedantic , but there are no human trials of mots-c, not of using it as a treatment. There are studies on measuring it in different groups of people or after exercise etc, but sadly not even basic toxicity or safety or dose ranging tests.
It is a chemical already in your body, which makes it a bit safer than something that does not normally belong there.
The doses used in mice in trials were over a pretty wide range from 0.5mg/kg/day to 10mg/kg/day. A rough translation works out to ( for a 70kg person ) 3.5mg to 70mg per day, human dose being about 1/10 mouse dose. Using an untested drug on humans, staying at the low end of the dose range would be safer, and that is the commonly used dose of 5mg daily to weekly. Many of the commonly used but untested peptides have doses in mouse studies way higher than are available such as KPV.
There has been a phase 1 trial of a modified version of mots c , usually interesting peptides in your body get modified before they start doing trials in humans, to improve pharmacokinetics and more importantly so it can be patented, there is zero money to be made otherwise. I cannot find the original papers on it in a quick look so I have no way of knowing how much it was altered. So there is some basic results on a related peptide which is useful and is an indicator of safety but not proof. This is way less data than needed to say a treatment is safe, just enough to go ahead with more trials. I cannot find anything after this.
"results from the multi-center, randomized, double-blind, placebo-controlled Phase 1a/1b clinical study of CB4211, under development for nonalcoholic steatohepatitis (NASH) and obesity. The study met its primary endpoint showing that CB4211 was well-tolerated and appeared safe with no serious adverse events. Evaluation of the exploratory pharmacodynamic endpoints from the Phase 1b stage of the study comparing CB4211 to placebo demonstrated robust and significant reductions in key biomarkers of liver damage, ALT and AST, a significant decrease in glucose levels, and a trend towards lower body weight after four weeks of treatment. Both the CB4211 and placebo groups had substantial reductions in liver fat content compared to baseline."
Unfortunately, especially for the most common peptides ( excluding the GLP's who have been studied ) most have not been tested in humans. The way influencers and many others talk about them intentionally or otherwise imply that the results of animal or cell studies are from humans. I have not much of a problem with people experimenting on themselves, but I think it is important to know beforehand if what you want to take has had at least some human testing. Mots c sounds great from its effects in rodents, and lots of people on this forum have taken it and as far as has been reported there have not been issues apart from localised allergic reactions being really common.
